DGXDGXHealthcare · Diagnostics & Research

DGX Stock Forecast: Quest Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$258
−0.24% on the day

The 17 Wall Street analysts covering Quest Diagnostics, Inc. hold a median 12-month price target of $260 — +0.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 93 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$28.5B
Ticker Nerd rank
93/ 100
Median analyst target
$260
Analysts covering
17
Revenue$3.0B+10.2% y/y
Operating income$459.0M
Net income$334.0M
Free cash flow$459.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.4%
1M
+9.0%
YTD
+51.4%
1Y
+40.1%
From 52W high
−1.4%
From 52W low
+51.5%
$171
$262
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Quest Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
93/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Revisions
91
Momentum
86
Issuance
85
Quality
80
Growth
69
Value
61
Accruals
58

Volatility (100): The share price has been relatively steady.

Accruals (58): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$160$180$200$220$240$260$280Jan 26Apr 26Jul 26Oct 26DGXHigh $279Median $260Low $235

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
9
Buy
8
Hold
0
Sell
$235
Low
$260
Median
$279
High

The green dot is the last close — the median target sits +0.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Oct 2026BarclaysMaintainsOverweight$250 → $260
21 Sept 2026Truist SecuritiesMaintainsHold$250 → $260
8 Sept 2026UBSMaintainsNeutral$232 → $245
28 July 2026JP MorganMaintainsNeutral$220 → $250
25 July 2026UBSMaintainsNeutral—
24 July 2026BairdMaintainsNeutral$236 → $255
24 July 2026BarclaysMaintainsOverweight$230 → $250
24 July 2026MizuhoMaintainsOutperform$235 → $260
24 July 2026Truist SecuritiesMaintainsHold$225 → $250
24 July 2026UBSMaintainsNeutral$220 → $232
13 July 2026BairdMaintainsNeutral$232 → $236
22 Apr 2026BairdMaintainsNeutral—
22 Apr 2026BarclaysMaintainsOverweight—
22 Apr 2026Truist SecuritiesMaintainsHold—
22 Apr 2026UBSMaintainsNeutral—
8 Apr 2026Evercore ISI GroupMaintainsIn-Line—
12 Feb 2026MizuhoMaintainsOutperform—
11 Feb 2026BarclaysMaintainsOverweight—
11 Feb 2026Evercore ISI GroupMaintainsIn-Line—
11 Feb 2026JefferiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DGX.

Market Radar

This page is one stock. Monday covers all of them.

DGX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DGX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Quest Diagnostics, Inc. returned +40.1% against +6.9% for the S&P 500, dividends included.

DGX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26DGXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+1.1%
Analysts raising
14
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.9×

Cheaper than 34% of US stocks

Price / sales
2.4×

Cheaper than 43% of US stocks

Price / book
3.8×

Cheaper than 25% of US stocks

EV / EBITDA
14.7×

Cheaper than 35% of US stocks

Growth & margins
Revenue growth (YoY)
10.0%

Higher than 53% of US stocks

Earnings growth (YoY)
27.3%

Higher than 65% of US stocks

Gross margin
33.7%

Higher than 40% of US stocks

Operating margin
14.9%

Higher than 72% of US stocks

Net margin
9.5%

Higher than 66% of US stocks

Returns & dividend
Return on equity
15.3%

Higher than 74% of US stocks

Return on assets
6.6%

Higher than 83% of US stocks

Dividend yield
1.3%

Higher than 28% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Quest Diagnostics, Inc. has a market value of $28.5B and an enterprise value of $34.5B.

  • Revenue in the twelve months to 30 June 2026: $11.6B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: $1.1B, a 9.6% net margin.

  • Diluted earnings per share, trailing twelve months: $9.42.

  • Free cash flow in the twelve months to 30 June 2026: $1.3B, after $554.0M of capital spending.

  • Quest Diagnostics, Inc. spent $363.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 110.0M.

  • Trailing P/E: 25.9×; forward P/E: 21.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.32%, paying out 25% of earnings.

  • Quest Diagnostics, Inc. employs 60,000 people — $193K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

DGX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
DGXQuest Diagnostics, Inc.$28.5B93
ILMNIllumina, Inc.$29.1B95
LHLabcorp Holdings, Inc.$30.4B88
MTDMettler-Toledo International, Inc.$34.1B96
NTRANatera, Inc.$39.6B70
IQVIQVIA Holdings, Inc.$40.5B83
WATWaters Corp.$43.2B52

Take a look at DGX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Quest Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about DGX

What is the DGX stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Quest Diagnostics, Inc. have a median 12-month price target of $260, with estimates ranging from $235 to $279. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DGX stock a buy right now?

Of the 17 analysts covering Quest Diagnostics, Inc., 9 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quest Diagnostics, Inc. 93 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DGX?

As at 21 Nov 2026, Quest Diagnostics, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will DGX stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +0.6% from the last close, and Ticker Nerd's factor model ranks Quest Diagnostics, Inc. 93 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DGX stock forecast for 2030?

No analyst covering Quest Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $235 to $279 over the next 12 months.

How has DGX stock performed over the past year?

Quest Diagnostics, Inc. returned +40.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Quest Diagnostics, Inc. do?

Quest Diagnostics Incorporated is a healthcare diagnostics company that provides diagnostic testing and related information services. Quest Diagnostics supports physicians, hospitals, patients, health plans, employers, and government agencies with routine clinical testing, advanced specialty testing, anatomic pathology, and consumer-ordered testing services.

Company

About Quest Diagnostics, Inc.

Quest Diagnostics Incorporated is a healthcare diagnostics company that provides diagnostic testing and related information services. Quest Diagnostics supports physicians, hospitals, patients, health plans, employers, and government agencies with routine clinical testing, advanced specialty testing, anatomic pathology, and consumer-ordered testing services. Its offerings include laboratory testing for areas such as cancer, heart disease, diabetes, infectious diseases, and genetic conditions, along with services for drug and alcohol screening, risk assessment, and healthcare information technology. The company operates a broad network of laboratories and patient service centers across the United States, helping connect sample collection, analysis, and reporting within the medical care process. Quest Diagnostics Incorporated plays a central role in the healthcare market by providing data and laboratory insights that support diagnosis, treatment decisions, and ongoing health management.

CEO Mr. James E. Davis · 60,000 employees · United States · https://www.questdiagnostics.com